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Background  and  purpose:  Although  several  studies  reported  that  drug-eluting  stents  (DES)  are  able  to
reduce restenosis  incidence  without  increasing  mortality,  concerns  still  exist  about their  safety  in ST-
segment  elevation  myocardial  infarction  (STEMI)  patients  mainly  for a possible  higher rate  of  in-stent
thrombosis.  Recent  evidence  suggests  a  better  safety  proﬁle  of  second-generation  DES,  but data  on their
outcome  in STEMI  are  still  poor.  In this  study  we evaluated  the  impact  on mortality  and  target  lesion
revascularization  (TLR)  of  DES  or  bare  metal  stent  (BMS)  implantation  in STEMI  patients  submitted  to
primary  angioplasty.
Methods and  subjects:  We  analyzed  mortality  and TLR  in 1150  STEMI  patients  during  a mean  43-month
follow-up after  DES  (44.6%)  or BMS  (55.4%)  implantation.  A  propensity  score  method  was  used  to  minimize
bias.  During  follow-up,  223  deaths  occurred.
Essential  results:  Unadjusted  for potential  confounders,  DES  implantation  was  associated  with  a signiﬁ-
cant  reduction  in all-cause  mortality  [hazard  ratio  (HR)  0.40;  95%CI  0.30–0.54]  and  TLR  (HR 0.55; 95%CI
0.36–0.86);  this  latter  was  conﬁrmed  after  propensity  score  analysis  (HR  0.39;  95%CI 0.21–0.67).  Second-
(n  =  179)  vs. ﬁrst-  (n = 337)  generation  DES  showed  a further  reduction  in TLR  (HR 0.17; 95%CI  0.05–0.57).
Adjusted  analyses  showed  a signiﬁcant  reduction  in  the  combined  end-point  of  all-cause  mortality  or
TLR  after  both  ﬁrst-  and  second-generation  DES  vs. BMS  implantation  with  a trend  to a lower risk  for
second-  vs.  ﬁrst-generation  DES.
Principal  conclusions:  DES  implantation  in STEMI  patients  showed  a signiﬁcant  reduction  in TLR  and  in
the  combined  endpoint  of  TLR  or mortality.  Second-generation  DES  showed  a more  protective  effect  on
the  combined  endpoint,  suggesting  that they  would  be preferred  in  this  setting.
©  2013  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Primary percutaneous coronary intervention (PCI) is the gold
tandard therapy for ST-segment elevation myocardial infarc-
ion (STEMI), its main aim being to obtain a rapid and effective
yocardial reperfusion through the culprit vessel re-opening,
hereby reducing mortality. Several randomized controlled trials
∗ Corresponding author at: Dipartimento del Cuore e dei Vasi, Azienda
spedaliero-Universitaria Careggi, Viale Morgagni, 85, 50134 Florence, Italy.
el.: +39 0557949577; fax: +39 0557947617.
E-mail address: cristinagiglioli@yahoo.it (C. Giglioli).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.09.007demonstrated that routine bare metal stent (BMS) implantation,
during primary PCI, was superior to balloon angioplasty alone
for its ability to reduce reocclusion or reinfarction [1–4]. How-
ever, angiographic follow-up of STEMI patients treated with BMS
showed a very high rate of in-stent restenosis [5–7]. Conversely,
the use of drug-eluting stents (DES) in the setting of primary PCI
was associated with a lower rate of in-stent restenosis with a
consequently lower need for repeat revascularizations [8]. How-
ever, no deﬁnitive conclusions have been drawn regarding their
effect on long-term mortality and the incidence of cardiovascular
events in this group of patients [9–16]. Furthermore, some con-
cerns still exist about the safety of DES in the setting of acute
myocardial infarction for two main reasons. Firstly, fears relating
vier Ltd. All rights reserved.
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o the higher rate of early and late in-stent thrombosis reported
n several studies leading to a higher mortality rate [17]. Sec-
ndly, the reduced possibility, in an urgent setting such as primary
CI, of completely ruling out all the possible contraindications to
 prolonged dual antiplatelet therapy (DAPT). However, conﬂict-
ng results regarding DES in STEMI patients were related almost
xclusively to ﬁrst-generation DES [9–11,13,14,18]. Recently, new
vidence has demonstrated a better safety proﬁle of second- vs.
rst-generation DES in patients with acute coronary syndromes,
ith a reduced incidence of in-stent thrombosis [19,20], but data
n outcome in the speciﬁc setting of STEMI are still poor. Therefore,
he choice of the safest stent in STEMI patients is still a matter for
ebate.
The aim of the present study was to evaluate, in STEMI patients
ubmitted to primary PCI, the impact of the type of stent implanted,
ither BMS  or ﬁrst- or second-generation DES, on repeat revascu-
arization rate and long-term mortality.
ethods
Between January 2004 and December 2009, 2058 patients
ith STEMI were submitted to primary PCI in the catheter-
zation laboratory of the University of Florence, a tertiary care
acility.
Only patients who had at least one DES or one BMS  implanted
n the course of the primary PCI were included in this analysis; 245
atients who were treated for the index event only with balloon
ngioplasty or with both types of stent were excluded from the
tudy. Among the remaining 1813 patients, 1150 were resident in
he Florence area (33 municipalities) and 663 in the surrounding
rovinces. We  limited our analysis to the 1150 inhabitants in the
lorence area. The study was approved by the local ethics commit-
ee.
Patients were divided into two groups according to the type
f stent implanted in the infarct-related artery (IRA) either BMS
Liberte’ and Express Stent, Boston Scientiﬁc, Natick, MA,  USA;
ulti Link Vision and Multi Link Mini-Vision Stent, Abbott Vas-
ular, Abbott Park, IL, USA; Driver and MicroDriver, Medtronic,
inneapolis, MN,  USA; Tecnic Carbostent, Sorin Biomedica, Milan,
taly) or DES (Paclitaxel Eluting Stent-PES, Taxus, Boston Scientiﬁc;
irolimus Eluting Stent-SES, Cypher, Cordis, Bridgewater, NJ, USA;
verolimus Eluting Stent-EES, Promus, Boston Scientiﬁc or XIENCE-
, Abbott Vascular; Zotarolimus Eluting Stent-ZES, Endeavor and
ndeavor Resolute, Medtronic).
The DES patients’ group was divided into two  further groups:
a) 337 patients implanted with a ﬁrst-generation DES (PES, SES)
nd (b) 179 patients implanted with a second-generation DES
EES, ZES). All PCIs were performed according to the international
uidelines on myocardial revascularization [21]. Coronary angiog-
aphy was performed through either the radial or the femoral
pproach. Before PCI all patients received a bolus of 70 IU/kg
f unfractionated heparin, 325 mg  of aspirin, and 300/600 mg
f clopidogrel loading dose. Administration of glycoprotein (Gp)
Ib/IIIa receptor inhibitors, the use of thrombus aspiration sys-
ems, and intravascular ultrasound analysis, as well as the
ype of stent implanted were at the interventional cardiolo-
ist’s discretion. Post-PCI, all patients received 75 mg/day of
lopidogrel for at least 12 months, 100 mg/day of aspirin indeﬁ-
itely, in addition to beta-blockers, angiotensin-converting enzyme
nhibitors, and statins if not contraindicated. Primary PCI was
erformed only in the IRA with the exception of patients with
ardiogenic shock; an intra-aortic balloon pump was used in
atients with severe hemodynamic instability or with cardiogenic
hock.ology 63 (2014) 296–301 297
Endpoints
The primary endpoints were: all-cause mortality, the occur-
rence of TLR, and the combined endpoint of all-cause mortality or
TLR during follow-up.
Life status after hospital discharge was assessed in December
2011 by consulting the Registry Ofﬁce of the municipalities of resi-
dence. TLR was  deﬁned as a PCI of the target lesion due to restenosis
or reocclusion within the stent or in an adjacent segment of 5 mm
distally or proximally to the edges of the stent. Data regarding TLR
were obtained by consulting the hospital discharge database fol-
lowing the index hospitalization and the procedural details were
obtained from the local catheterization laboratory database. All
PCIs performed in the study population after the index revasculari-
zation were ischemia-driven and all the procedures were reviewed
by two interventional cardiologists unaware of the type of stent
implanted in the index procedure to establish the occurrence of
TLR as described above.
Subsequent revascularizations of other coronary arteries did not
constitute an endpoint.
Endpoints were assessed for the entire follow-up period.
Statistical analysis
Categorical variables were given as a percentage and compared
with the 2 test. As continuous variables were non-normally dis-
tributed at the Shapiro–Wilk test, they were described as median
and interquartile range and compared using the Wilcoxon’s rank-
sum test.
A propensity score method was used to minimize bias related to
the nonrandom assignment of stent type. The propensity score was
calculated introducing in the ﬁnal model the following variables:
age-classes, gender, diabetes mellitus, smoking habit, dyslipidemia,
chronic obstructive pulmonary disease, Killip class, heart rate, and
coronary angiographic characteristics (statistically signiﬁcant at
univariate analysis) as well as other variables such as previous acute
myocardial infarction, previous PCI, and hypertension (not statisti-
cally signiﬁcant at univariate analysis, but potential predictors).
The propensity score reﬂects the individual patient’s predicted
probability of receiving treatment with DES given the observed
set of covariates and it is used to make an adjustment for covari-
ates during calculation of the prognostic effect. When building the
propensity score using a logistic regression model, only covariates
that occurred pre-treatment were included (baseline conditions
and clinical presentation). Two separate methods were used to
compare outcomes after DES or BMS:
(1) A classical approach using the Cox proportional hazards regres-
sion model to estimate the effect of the type of stent on all-cause
mortality, TLR, and the combined endpoints, adjusting for pro-
cedural aspects (thrombus aspiration and Gp IIb/IIIa inhibitor
use) and propensity score included as a continuous covariate.
Hazard ratios (HR) and 95% conﬁdence intervals (CI) were cal-
culated. The methods proposed by Grambsch and Therneau [22]
and by May  and Hosmer [23] were used to check the propor-
tional hazard assumption and the goodness-of-ﬁt of the models,
respectively. A p-value <0.05 was  considered statistically signif-
icant.
(2) In the second approach, one-to-one nearest neighbor match-
ing was  performed to compare outcomes after undergoing
PCI (matched-pair analysis). In this case, the matched pairs
were characterized by having a similar propensity score. To
evaluate the success of the propensity score matching we  com-
pared covariates in the groups before and after matching. All
baseline characteristics that had been signiﬁcantly different
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Table 2
Angiographic and procedural features by stent type.
BMS  group DES group p
Patients 634 516
Time from symptoms onset to PCI
(min)
222 (150–315) 210 (150–300) 0.834
Culprit vessel, %
Right coronary artery 43.7 27.1
<0.001
Left circumﬂex 15.0 14.3
Left anterior descending 39.1 55.4
Left main 1.4 1.4
Bypass graft 0.5 1.2
Intermediate branch 0.3 0.6
Extension of coronary disease, %
One-vessel disease 48.6 47.7
0.778Two-vessel disease 28.4 27.6
Three-vessel disease 23.1 24.7
Left main disease, % 8.0 4.9 0.030
Collateral circulation, % 13.1 12.6 0.803
TIMI ﬂow pre-PCI, %
0 70 58
<0.001
1  21.1 25
2  7.4 14.7
3  1.4 2.3
TIMI ﬂow post PCI, %
0 0.5 0.0
0.052
1  0.6 0.8
2  3.5 1.4
3  95.4 97.9
Thrombus aspiration, % 52.6 48.6 0.181
Glycoprotein IIb–IIIa inhibitors, % 54.7 72.2 <0.001
Stent number, %
1 72.7 70.9
0.63
2  19.9 22.5
3  6.3 5.6
≥4  1.1 0.9
Stent diameter
<3 mm,  % 36.8 44.2
0.011>  3 mm,  % 63.4 55.898 C. Giglioli et al. / Journal o
(unbalanced) between groups in the overall study were bal-
anced on the propensity-matched pairs.
Cox proportional hazard models adjusted for procedural aspects
nd stratiﬁed were ﬁtted on the matched pairs [24].
These two approaches are well-accepted methods of applying
ropensity scores [24–26].
Analyses were performed using STATA statistical package (ver-
ion 11.0, Stata Corporation, College Station, TX, USA).
esults
Out of 1150 STEMI patients with primary PCI (mean age:
8.2 ± 12.5 years), 634 (55.4%) received a BMS  and 516 (44.6%)
eceived a DES in the IRA.
In comparison with BMS  patients, DES patients were sig-
iﬁcantly younger, more often men, and more likely to be
urrent smokers and dyslipidemic. Among cardiovascular and non-
ardiovascular comorbidities, only chronic obstructive pulmonary
isease was less frequent in DES patients (p = 0.035) (Table 1).
Patients who received DES showed signiﬁcantly lower levels
f glycemia and troponin I, a lower Killip class, a higher ejec-
ion fraction (EF) (Table 1) and a higher grade of anterograde ﬂow
re-PCI in the IRA (Table 2). In comparison to BMS, DES were signif-
cantly longer and with a diameter less than 3 mm,  more frequently
mplanted in the left anterior descending artery (LAD), and associ-
ted with Gp IIb–IIIa inhibitor administration (Table 2).
mpact of type of stent on all-cause mortality
During the follow-up period (mean duration 43 months), 223
eaths occurred. The overall survival probability for the entire
ohort was 79% (72% for BMS; 88% for DES, p < 0.001).
In the unadjusted analysis, DES was associated with a statis-
ically signiﬁcant 60% reduction in all-cause mortality (HR 0.40;
5%CI 0.30–0.54). The reduction was not signiﬁcant anymore when
able 1
aseline characteristics at presentation of patients undergoing PCI by stent type.
BMS  group DES group p
Patients 634 516
Age, yearsa 74 (63–82) 63 (55–71) <0.001
Males, % 33.7 49.1 <0.001
BMI, kg/m2 a 26 (23–28) 26 (24–28) 0.229
Diabetes mellitus, % 28.5 22.8 0.052
Hypertension, % 55.9 49.6 0.062
Smoker, % 56.3 65.5 0.005
Dyslipidemia, % 33.2 41.9 0.007
Chronic kidney disease, % 5.9 5.2 0.668
COPD% 10.1 6.2 0.035
Previous AMI, % 11.4 11.2 0.938
Previous angina, % 21.9 23.1 0.662
Previous PCI, % 8.3 11.4 0.117
Previous CABG, % 1.8 1.7 0.924
Systolic pressurea 130 (115–146) 130 (115–150) 0.809
Heart ratea 78 (67–88) 75 (66–85) 0.039
Killip class
I-II, % 86.8 92.1
0.007III-IV, % 13.2 7.9
EFa 45 (37–50) 48 (40–55) 0.001
Glycemiaa 1.39 (1.14–1.81) 1.25 (1.06–1.52) <0.001
Serum creatininea 0.9 (0.8–1.2) 0.9 (0.8–1.1) 0.344
CK-MBa 172 (79–331) 155 (65–294) 0.156
TnI  (ng/mL)a 80 (35–174) 64 (26–147) 0.036
CI, percutaneous coronary intervention; BMS, bare metal stent; DES, drug elu-
ing stent; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
MI, acute myocardial infarction; CABG, coronary artery bypass graft; EF, ejection
raction; CK-MB, creatinine kinase-myocardial band; Tn, troponin.
a Median and interquartile range.
Total stent lengtha 20 (15–28) 23 (18–32) <0.001BMS, bare metal stent; DES, drug-eluting stent; PCI, percutaneous coronary inter-
vention; TIMI, thrombolysis in myocardial infarction.
a Median and interquartile range.
the propensity score was  included as a continuous covariate (HR
0.76; 95%CI 0.53–1.10) and when the analysis was stratiﬁed by
the DES generation group. Nevertheless, the matched-pair analysis
indicated a signiﬁcant reduction in mortality in the DES group (HR
0.61; 95%CI 0.39–0.95) (Table 3).
Moreover, during follow-up, we observed 49 myocardial rein-
farctions without any signiﬁcant difference in relation to the type
of stent implanted [26 events (4.1%) in patients treated with BMS
vs. 23 events (4.4%) in those treated with DES, p = n.s.].
As far as the causes of death are concerned, data are available
only for 92 patients who  died in hospital during the index admission
or in a subsequent hospitalization. In particular, 63 of them died of
cardiac causes (49 myocardial infarction, 7 other ischemic heart
diseases, 2 cardiac arrest, and 5 heart failure).
Impact of type of stent on TLR occurrence
During the follow-up period, 89 TLR were performed (84% dur-
ing the ﬁrst year after the index event).
The TLR-free survival probability for the entire cohort was  92%
(91% for BMS; 94% for DES, p < 0.028).
Unadjusted for any potential confounders, DES was  associated
with a statistically signiﬁcant 45% reduction in TLR occurrence
(HR 0.55; 95%CI 0.36–0.86). This association remained signiﬁcant
when the propensity score was included in the model as a con-
tinuous covariate (HR 0.39; 95%CI 0.21–0.67) and in the analysis
stratiﬁed by DES generation group, with a strong reduction for the
second-generation DES (HR 0.17; 95%CI 0.05–0.57). Results were
C. Giglioli et al. / Journal of Cardiology 63 (2014) 296–301 299
Table  3
Impact of DES on all-cause mortality and target lesion revascularization occurrence.
Cox proportional hazard models Death TLR Combined endpoint
Hazard
ratioa
95% CI p Hazard
ratioa
95% CI p Hazard
ratioa
95% CI p
Unadjusted 0.40 0.30–0.54 <0.001 0.55 0.36–0.86 0.008 0.43 0.33–0.55 <0.001
Adjustedb
Model with propensity scorec stratiﬁed
by stent generation
0.76 0.53–1.10 0.145 0.39 0.23–0.68 0.001 0.58 0.42–0.79 0.001
DES  ﬁrst generation 0.82 0.54–1.22 0.327 0.48 0.27–0.85 0.012 0.64 0.46–0.91 0.011
DES  second generation 0.59 0.32–1.09 0.094 0.17 0.05–0.57 0.004 0.38 0.22–0.68 0.001
Propensity matching-pair analysis 0.61 0.39–0.95 0.028 0.41 0.23–0.73 0.003 0.47 0.32–0.68 <0.001
CI, conﬁdence interval; DES, drug-eluting stent; BMS, bare metal stent.
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the better stent for STEMI patients; indeed, over the past few years,
the use of DES for primary PCI has generated a variety of responsesa Reference category: BMS  use.
b Adjusted for glycoprotein IIb–IIIa inhibitors and thrombus aspiration.
c Propensity score as a continuous variable.
imilar in the matched-pair analysis (OR 0.41; 95%CI 0.23–0.73)
Table 3).
mpact of type of stent on combined endpoint (all-cause mortality
r TLR occurrence)
Finally, we considered the effect of type of stent on the com-
ined endpoint of all-cause mortality and TLR occurrence during
he entire follow-up period. Unadjusted analysis showed a 57%
eduction on combined endpoint for patients treated with DES
HR 0.43; 95%CI 0.33–0.55). All adjusted models showed signiﬁ-
ant results, and a consistent risk reduction of between 40% and
0% was found in the different analytical approaches (Table 3).
A detailed analysis was performed on a 1-year combined end-
oint.
Fig. 1 shows the observed 1-year event-free survival
aplan–Meier curves (a) and estimated (adjusted for propen-
ity score as a continuous variable, thrombus aspiration and Gp
ig. 1. One-year observed (a) and estimated (b) event-free survival by type of stent.
MS, bare metal stent; DES, drug-eluting stent.IIb/IIIA inhibitors) curves (b) among BMS  and ﬁrst- as well as
second-generation DES patients. The adjusted analysis (Fig. 2)
showed a statistically signiﬁcant lower risk of the combined
endpoint in the ﬁrst year of follow-up in DES groups (HR 0.50;
95%CI 0.34–0.73) in comparison with BMS  (reference category)
and suggested a lower risk in second-generation DES (HR 0.42;
95%CI 0.23–0.77) compared with ﬁrst-generation DES (HR 0.55;
95%CI 0.36–0.85).
Discussion
The present study again raises questions regarding the choice ofranging from enthusiasm to consternation [27]. In our study pop-
ulation of unselected STEMI patients who underwent primary PCI,
Fig. 2. Impact of type of stent on one-year combined endpoint (all-cause mortality
or  target lesion revascularization) in Cox regression model adjusted for propensity
score, thrombus aspiration and IIb–IIIa inhibitors. Hazard ratios (HR) and 95% con-
ﬁdence intervals (reference category: bare metal stent group). DES, drug-eluting
stent.
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ES implantation was associated with a signiﬁcant reduction in
he need for TLR. Considering long-term mortality, a signiﬁcant
eduction with DES was found only when a more sophisticated
tatistical method was applied, whereas no signiﬁcant differences
ere found between patients treated with DES or BMS in the other
ethodological approaches.
Nevertheless, when the combined endpoint of all-cause mortal-
ty or TLR was considered, DES conﬁrmed a more protective effect
han BMS.
In addition, all the analyses considering the different endpoints
uggested a further lower risk associated with the use of second-
eneration DES.
Therefore, our results are in agreement with previous studies
eporting a reduction in TLR in STEMI patients treated with DES
mplantation [12,14] but, at variance with them, they also suggest
 reduction in all-cause mortality with DES and a more protective
ffect on the different outcomes of second-generation DES.
Although the main aim of primary PCI is a rapid and effec-
ive myocardial reperfusion, the reduction in TLR rate can also
e considered an important goal in STEMI patients for two main
easons: ﬁrstly, a reduction in repeat revascularization improves
he patient’s quality of life; secondly, in a signiﬁcant percentage of
ases, restenosis can express itself as an acute coronary syndrome,
azardous for the patient and with high costs for the community
28].
Therefore, the ability of DES implantation in reducing TLR can
e considered favorable also for STEMI patients on condition that
he use of this type of stent does not increase the incidence
f other major adverse events likely to increase the mortality
ate.
In our study population, not only we observed no increase in all-
ause mortality in patients treated with DES but, when a propensity
core matching-pair analysis was performed, we saw that the all-
ause mortality rate was signiﬁcantly lower in the DES group than
n the BMS  group. Although, in-stent thrombosis was  not included
s an endpoint in our study and we were consequently unable
o know its real incidence, we can nevertheless assume that DES
mplantation in our patients was not associated with an increased
ccurrence of this complication that in previous reports was  fatal
n 50% of cases [29].
Moreover, the mean duration of our follow-up was  43
onths, a signiﬁcantly longer period than the 12 months usually
ecommended for the DAPT, suggesting that, also after the discon-
inuation of this therapy, DES implantation in our STEMI patients
as not associated with an increased mortality rate in comparison
o BMS.
The risk of a higher incidence of in-stent thrombosis in STEMI
atients treated with DES, leading to an increase in mortality
hereby wiping out the advantages of a rapid reperfusion due to
he primary PCI, has become a pivotal issue over the past few years
nd only recently both randomized controlled clinical trials [19]
nd meta-analysis [30] suggested the safety and efﬁcacy of DES in
rimary PCI [31]. In particular, our analysis strengthens this latter
ssue through the results of a real world study that faithfully reﬂects
he daily activity of our tertiary center. Nevertheless, cardiologists
re still suspicious about DES implantation in STEMI patients, espe-
ially because of the difﬁculty in obtaining clinical history in the
etting of primary PCI with an incomplete overseeing of contraindi-
ations to a prolonged DAPT. However, in our opinion, asking some
imple questions, which can be done in the catheterization lab-
ratory during primary PCI (regarding a possible planned surgical
ntervention that cannot be postponed, a history of gastrointestinal
r urological bleeding, previous allergic reactions to aspirin, and the
illingness of the patient to undergo DAPT for at least 12 months),
an aid the interventional cardiologist in the choice of the better
tent for each individual patient.ology 63 (2014) 296–301
Our results also showed a signiﬁcant reduction in the combined
endpoint of all-cause mortality or TLR occurrence with the use of
DES in comparison to BMS. As new evidence has emerged on an
improved safety proﬁle of second-generation DES [32], we  also per-
formed a sub-analysis on patients treated with second-generation
DES. Patients who  underwent EES or ZES implantation showed a
consistent reduction in the combined endpoint of all-cause mor-
tality or TLR compared to BMS  and to ﬁrst-generation DES. This
result was signiﬁcantly maintained after multivariate analysis and
propensity score matching (Figs. 1 and 2).
There are some signiﬁcant differences between second- and
ﬁrst-generation DES. First, the drug elution proﬁle is different. In the
ZES and EES systems, most of the anti-proliferative drug is eluted
by the ﬁrst month post-PCI, when most of the proliferative activity
exists. After this period, the drug does not inhibit healing and the
coverage of stent struts, thus reducing the occurrence of late and
very late stent thrombosis [33,34]. The second difference is that
ZES are coated with biocompatible hydrophilic phosphorylcholine
polymers and have low-proﬁle thin stent struts capable of inducing
less inﬂammation when compared to ﬁrst-generation DES [35] and
ensuring an early endothelial coverage [36].
Limitations
Our study had several limitations. First, this study was  obser-
vational on prospectively collected data, therefore it was  prone to
a number of biases. To address some of these limitations, we  con-
ducted a propensity score analysis. The score analysis may  reduce
selection bias, but can only check for measured characteristics, and
is therefore unable to completely replicate the random treatment
assignment of a clinical trial. Thus, biases may  remain that are not
accounted for in this analysis, such as the presence of cancer or the
reason for which in a single patient, a DES was chosen over a BMS.
However, we extensively analyzed baseline clinical and angiogra-
phic characteristics predictive for DES implantation: younger age,
LAD as culprit vessel, and a grade of occlusion less than 98%.
Another limitation is the lack of knowledge regarding the dura-
tion of DAPT used in the 2 groups of patients even though, at our
institution, this therapy is recommended for at least a 12-month
period in all patients with STEMI submitted to primary PCI, regard-
less of the type of stent implanted. Finally, myocardial infarction
and stent thrombosis were not included as endpoints. This is poten-
tially important considering the concerns about stent thrombosis
of DES in STEMI patients.
Conclusions
In conclusion, our data, despite several limitations, suggested
that DES implantation in STEMI patients can be considered safe,
in fact DES in our analysis did not determine an increased mor-
tality showing a positive trend toward its reduction. It also seems
preferable to BMS  because of its ability to reduce TLR and the com-
bined endpoint of all-cause mortality or TLR. Our data suggest that
the advantages are more evident in patients treated with second-
generation DES in comparison to BMS  and ﬁrst-generation DES.
Therefore, on the basis of our results, we suggest that currently
second-generation DES should be preferred during primary PCI, in
particular for their impact on death or TLR. However, it is reasonable
to suppose that further advantages will soon be forthcoming thanks
to the use of new third-generation stents.References
[1] Stone GW,  Grines CL, Cox DA, Garcia E, Tcheng JE, Grifﬁn JJ, Guagliumi G,
Stuckey T, Turco M,  Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab
and  Device Investigation to Lower Late Angioplasty Complications (CADILLAC)
f Cardi
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[C. Giglioli et al. / Journal o
Investigators. Comparison of angioplasty with stenting, with or without abcix-
imab, in acute myocardial infarction. N Engl J Med  2002;346:957–66.
[2] De Luca G, Suryapranata H, Stone GW,  Antoniucci D, Biondi-Zoccai G, Kastrati A,
Chiariello M,  Marino P. Coronary stenting versus balloon angioplasty for acute
myocardial infarction: a meta-regression analysis of randomized trials. Int J
Cardiol 2008;126:37–44.
[3] Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman
EM.  Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoro-
nary stents improves survival in non-ST-segment elevation acute coronary
syndromes: a meta-analysis and review of the literature. Am J Cardiol
2004;93:830–5.
[4] Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE,  Spacek R, Widimsky P,
McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive
strategies in patients with acute coronary syndromes: a collaborative meta-
analysis of randomized trials. JAMA 2005;293:2908–17.
[5] Serruys PW,  de Jaegere P, Kiemanaij F, Macaya C, Rutsch W,  Heyndrickx G,
Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo
A,  Goy JJ, van den Heuvel P, et al., for the Benestent Study Group. A comparison
of  balloon-expandable-stent implantation with balloon angioplasty in patients
with coronary artery disease. N Engl J Med  1994;331:489–95.
[6] Fischman DL, Leon MB,  Baim DS, Schatz RA, Savage MP,  Penn I, Detre K, Veltri
L,  Ricci D, Nobuyoshi M,  Cleman M,  Heuser R, Almond D, Teirstein PS, Fish
RD, et al. A randomized comparison of coronary-stent placement and bal-
loon angioplasty in the treatment of coronary artery disease. N Engl J Med
1994;331:496–501.
[7] Cutlip DE, Chauha MS,  Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz
RE.  Clinical restenosis after coronary stenting: perspectives from multi-center
clinical trials. J Am Coll Cardiol 2002;40:2082–9.
[8] Laarman GJ, Suttorp MJ,  Dirksen MT,  van Heerebeek L, Kiemeneij F, Slagboom
T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M.  Paclitaxel-eluting
versus uncoated stents in primary percutaneous coronary intervention. N Engl
J  Med 2006;355:1105–13.
[9] Menichelli M,  Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A,
Alborino D, Azzellino A, Violini R. Randomized trial of Sirolimus-Eluting Stent
Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll
Cardiol 2007;49:1924–30.
10] Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS,  Merkely
B, Erglis A, Margheri M,  Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C, et al.
Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl
J  Med 2006;355:1093–104.
11] Van der Hoeven BL, Liem SS, Jukema JW,  Suraphakdee N, Putter H, Dijk-
stra  J, Atsma DE, Bootsma M,  Zeppenfeld K, Oemrawsingh PV, van der
Wall EE, Schalij MJ. Sirolimus-eluting stents versus bare-metal stents in
patients with ST-segment elevation myocardial infarction: 9-month angiog-
raphic and intravascular ultrasound results and 12-month clinical outcome
results from the MISSION! Intervention Study. J Am Coll Cardiol 2008;51:
618–26.
12] Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di
Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M,  Varenne O, Dirksen MT,  Per-
coco G, Varricchio A, et al. Meta-analysis of randomized trials on drug-eluting
stents vs. bare-metal stents in patients with acute myocardial infarction. Eur
Heart J 2007;28:2706–13.
13] Valgimigli M,  Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cic-
chitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G,
Boersma E, Ferrari R, et al. Tiroﬁban and sirolimus-eluting stent vs abciximab
and  bare-metal stent for acute myocardial infarction: a randomized trial. JAMA
2005;293:2109–17.
14] Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, Hoye A,
McFadden E, Sianos G, Smits PC, van der Giessen WJ,  de Feyter P, van Dom-
burg RT, Serruys PW.  Short- and long-term clinical beneﬁt of sirolimus-eluting
stents compared to conventional bare stents for patients with acute myocardial
infarction. J Am Coll Cardiol 2004;43:704–8.
15] Slottow TL, Steinberg DH, Roy P, Javaid A, Buch AN, Okabe T, Xue Z, Smith
K,  Torguson R, Pichard AD, Satler LF, Suddath WO,  Kent KM, Waksman R.
Drug-eluting stents are associated with similar cardiovascular outcomes when
compared to bare metal stents in the setting of acute myocardial infarction.
Cardiovasc Revasc Med  2008;9:24–8.
16] Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M,  da Costa
BR,  Mach F, Lüscher TF, Meier B, Windecker S, Jüni P. Comparison of drug-
eluting stents with bare metal stents in patients with ST-segment elevation
myocardial infarction. Eur Heart J 2012;33:977–87.
17] Pﬁsterer ME.  Late stent thrombosis after drug-eluting stent implantation for
acute myocardial infarction. Circulation 2008;118:1117–9.
[ology 63 (2014) 296–301 301
18] Adachi T, Kotani J, Ikari Y, Kyo E, Nakamura M,  Yokoi H. The Japanese expe-
rience with sirolimus-eluting stent implantation in the infarct-related artery:
ﬁve years of observation from the J-PMS study. J Cardiol 2013;61:321–5.
19] Stone GW,  Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,
Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M,
Parise H, Mehran R, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus
bivalirudin monotherapy and paclitaxel-eluting stents versus bare metal stents
in  acute myocardial infarction (HORIZONS-AMI): ﬁnal 3-year results from a
multicentre, randomised controlled trial. Lancet 2011;377:2193–204.
20] Suzuki H. Safety and efﬁcacy of drug-eluting stents in patients with acute
myocardial infarction – from ﬁrst generation to second generation of drug-
eluting stents. J Cardiol 2013;61:378–9.
21] Task Force on Myocardial Revascularization of the European Society of Cardi-
ology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),
European Association for Percutaneous Cardiovascular Interventions (EAPCI),
Wijns W,  Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K,
James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, et al. Guidelines on
myocardial revascularization. Eur Heart J 2010;31:2501–55.
22] Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based
on weighted residuals. Biometrika 1994;81:515–26.
23] May  S, Hosmer DW.  A simpliﬁed method of calculating an overall goodness-
of-ﬁt test for the Cox proportional hazards model. Lifetime Data Anal
1998;4:109–20.
24] Austin PC. A critical appraisal of propensity-score matching in the medical
literature between 1996 and 2003. Stat Med  2008;27:2037–49.
25] D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison
of a treatment to a non-randomized control group. Stat Med  1998;17:2265–81.
26] D’Agostino Jr RB. Propensity scores in cardiovascular research. Circulation
2007;115:2340–3.
27] Hannan EL, Racz M,  Walford G, Holmes DR, Jones RH, Sharma S, Katz S, King
3rd SB. Drug-eluting versus bare-metal stents in the treatment of patients
with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv
2008;1:129–35.
28] Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo
F,  Kimura T, Briguori C, Sabatè M,  Kim HS, De Waha A, Kedhi E, Smits PC,
Kaiser C, Sardella G, et al. Stent thrombosis with drug-eluting and bare-
metal stents: evidence from a comprehensive network meta-analysis. Lancet
2012;379:1393–402.
29] Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM,  Stankovic G, Airoldi F,
Chieffo A, Montorfano M,  Carlino M,  Michev I, Corvaja N, Briguori C, Gerckens U,
Grube E, et al. Incidence, predictors and outcome of thrombosis after successful
implantation of drug eluting stents. JAMA 2005;293:2126–30.
30] Vink MA,  Dirksen MT,  Suttorp MJ,  Tijssen JG, van Etten J, Patterson MS, Slag-
boom T, Kiemeneij F, Laarman GJ. 5-Year follow-up after primary percutaneous
coronary intervention with a paclitaxel-eluting stent versus a bare-metal
stent in acute ST-segment elevation myocardial infarction: a follow-up study
of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial
Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011;4:
24–9.
31] Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M,
Di  Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA,  Schalij
MJ.  Drug-eluting stents in acute myocardial infarction: updated meta-analysis
of  randomized trials. Clin Res Cardiol 2010;99:345–57.
32] Hofma SH, Brouwer J, Velders MA,  van’t Hof AW,  Smits PC, Queré M,  de Vries
CJ,  van Boven AJ. Second-generation everolimus eluting stents versus ﬁrst gen-
eration sirolimus eluting stents in acute myocardial infarction: 1 year results
of  randomized XAMI (XienceV Stent vs Cypher Stent in Primary PCI for Acute
Myocardial Infarction) Trial. J Am Coll Cardiol 2012;60:381–7.
33] Nebeker JR, Virmani R, Bennett CL, Hoffman JM,  Samore MH,  Alvarez J, Davidson
CJ,  McKoy JM,  Raisch DW,  Whisenant BK, Yarnold PR, Belknap SM,  West DP,
Gage JE, Morse RE, et al. Hypersensitivity cases associated with drug-eluting
coronary stents: a review of available cases from the Research on Adverse Drug
Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175–81.
34] Finn AV, Joner M,  Nakazawa G, Kolodgie F, Newell J, John MC,  Gold HK, Virmani
R.  Pathological correlates of late drug-eluting stent thrombosis: strut coverage
as  a marker of endothelialization. Circulation 2007;115:2435–41.
35] Virmani R. Next generation DES: results from preclinical data. Available at:
http://www.summitmd.com/pdf/pdf/080801 6.pdf36] Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King 3rd SB, Raizner AE, Holmes
DR, Kereiakes DJ, Topol EJ. Major clinical events after coronary stenting. The
multicenter registry of acute and elective Gianturco–Roubin stent placement.
The Gianturco–Roubin Intracoronary Stent Investigator Group. Circulation
1994;89:1126–37.
